Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesUnited Therapeutics Corporation

United Therapeutics Corporation

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
562.02 USD -3.70 ( 0.65%)
Last update at 2026-11-06T21:00:00Z
VOLUME
454900
Market Cap
21460.36M
P/E
17.93

Momentum Score

…

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
559.41
Low
569.45
High
52 Week Price Range
402.50
Low
609.35
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
565.72
Dividend Yield
-
Revenue TTM
3154.50M
Revenue Per Share
72.85
Gross Profit TTM
2717.30M
Debt / Equity
0.01
ROE
19.32%
Net Debt
-1519.50M
ROCE
23.68%
Diluted EPS TTM
27.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1713.90M 1539.00M 1274.30M 950.60M 593.90M
Net income 1334.70M 1195.10M 984.80M 727.30M 475.80M
Selling general administrative 612.50M 542.30M 395.30M 416.20M 402.60M
Selling and marketing expenses 118.60M 96.30M 81.80M 70.80M 64.40M
Gross profit 2798.30M 2567.70M 2070.00M 1789.60M 1563.00M
Reconciled depreciation 85.60M 72.50M 53.20M 51.30M 49.90M
Ebit 1733.40M 1581.90M 1333.60M 979.70M 555.90M
Ebitda 1819.00M 1654.40M 1386.80M 984.70M 614.80M
Depreciation and amortization 85.60M 72.50M 53.20M 5.00M 58.90M
Non operating income net other - - - 3.30M 56.60M
Operating income 1517.20M 1377.00M 1184.90M 979.70M 555.90M
Other operating expenses 1665.50M 1500.40M 1142.60M 956.60M 1129.60M
Interest expense 19.50M 42.90M 59.30M 32.40M 18.60M
Tax provision 379.20M 343.90M 289.50M 223.30M 118.10M
Interest income 192.00M 199.10M 162.70M 45.20M 16.70M
Net interest income 172.50M 156.20M 103.40M 12.80M -1.90M
Income tax expense 379.20M 343.90M 289.50M 223.30M 118.10M
Total revenue 3182.70M 2877.40M 2327.50M 1936.30M 1685.50M
Total operating expenses 1281.10M 1190.70M 885.10M 809.90M 1007.10M
Cost of revenue 384.40M 309.70M 257.50M 146.70M 122.50M
Total other income expense net 196.70M 162.00M 89.40M -29.10M 38.00M
Net income from continuing ops 1334.70M 1195.10M 984.80M 727.30M 475.80M
Net income applicable to common shares - - - 727.30M 475.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7880.00M 7364.00M 7167.00M 6044.50M 5169.10M
Intangible assets 116.50M 79.60M 80.50M 16.50M 16.60M
Other current assets 1612.10M 169.70M 166.20M 219.20M 100.40M
Total liab 783.80M 920.00M 1182.20M 1247.80M 1210.20M
Total stockholder equity 7096.20M 6444.00M 5984.80M 4796.70M 3958.90M
Deferred long term liab - - - 10.50M 6.90M
Other current liab 546.20M 432.10M 71.00M 339.10M 301.60M
Common stock 0.80M 0.80M 0.70M 0.70M 0.70M
Capital stock 0.80M 0.80M 0.70M 0.70M 0.70M
Retained earnings 8556.90M 7222.20M 6027.10M 5042.30M 4315.00M
Other liab - - - 76.80M 104.80M
Good will 32.30M 32.30M 33.70M 28.00M 28.00M
Other assets - - - 413.50M 370.10M
Cash 1557.10M 1697.20M 1207.70M 961.20M 894.80M
Total current liabilities 560.60M 738.10M 804.40M 343.20M 305.40M
Current deferred revenue - - 327.80M - -
Net debt -1519.50M -1397.20M -507.70M -161.20M -94.80M
Short term debt 7.30M 300.00M 400.00M - -
Short long term debt - 300.00M 400.00M - -
Short long term debt total 37.60M 300.00M 700.00M 800.00M 800.00M
Other stockholder equity -1462.40M -775.60M -30.20M -190.80M -333.80M
Property plant equipment - - - 861.50M 780.90M
Total current assets 3702.50M 3873.90M 3551.00M 3380.30M 2323.60M
Long term investments 1776.70M 1475.30M 1909.80M 1316.20M 1649.90M
Net tangible assets - - - 4752.20M 3914.30M
Short term investments 1363.20M 1569.80M 1786.40M 1877.50M 1035.90M
Net receivables 350.20M 279.30M 278.90M 220.40M 198.70M
Long term debt - - 300.00M 800.00M 800.00M
Inventory 183.10M 157.90M 111.80M 102.00M 93.80M
Accounts payable 7.10M 6.00M 5.60M 4.10M 3.80M
Accumulated other comprehensive income 0.90M -3.40M -12.80M -55.50M -23.00M
Common stock total equity - - - 0.70M 0.70M
Retained earnings total equity - - - 5042.30M 4315.00M
Non currrent assets other 196.90M 222.10M 151.80M 114.30M 108.20M
Non current assets total 4177.50M 3490.10M 3616.00M 2664.20M 2845.50M
Long term debt total - - - 800.00M 800.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 40.10M 417.20M -951.00M -683.60M -366.10M
Change to liabilities - - - 44.50M -12.50M
Total cashflows from investing activities -551.30M 417.20M -719.60M -811.50M -486.90M
Net borrowings -300.00M -400.00M -100.00M -7.50M -
Total cash from financing activities -1150.00M -1254.80M -11.90M 75.40M 44.80M
Change to operating activities - - - -150.60M -112.90M
Net income 1334.70M 1195.10M 984.80M 727.30M 475.80M
Change in cash -140.10M 489.50M 246.50M 66.40M 156.10M
Begin period cash flow 1697.20M 1207.70M 961.20M 894.80M 738.70M
End period cash flow 1557.10M 1697.20M 1207.70M 961.20M 894.80M
Total cash from operating activities 1561.20M 1327.10M 978.00M 802.50M 598.20M
Depreciation 85.60M 72.50M 53.20M 51.30M 49.90M
Other cashflows from investing activities 1845.70M -28.50M -23.00M 10.90M -
Dividends paid - - 98.00M - -
Change to inventory -52.60M -46.90M -13.60M -13.40M -7.50M
Change to account receivables -70.90M -0.40M -58.50M -21.70M -41.30M
Sale purchase of stock -1000.00M -1012.20M -13.80M -11.40M -10.80M
Other cashflows from financing activities -33.10M 157.40M 101.90M 798.40M 50.00M
Change to netincome - - - 169.60M 246.70M
Capital expenditures 520.50M 246.50M 230.40M 138.80M 120.80M
Change receivables - - - -21.70M -41.30M
Cash flows other operating - - - 572.20M 272.60M
Cash and cash equivalents changes - - - 66.40M 156.10M
Change in working capital -106.40M -60.20M -97.80M -141.20M -174.20M
Stock based compensation 147.70M 144.00M 39.10M 106.80M 138.50M
Other non cash items 2.00M -24.30M -1.30M 58.30M 65.90M
Free cash flow 1040.70M 1080.60M 747.60M 663.70M 477.40M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
UTHR
United Therapeutics Corporation		 -3.70
0.65%		 562.02 17.93 16.58 6.80 3.37 5.85 11.00
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

1000 Spring Street, Silver Spring, MD, United States, 20910

301 608 9292

https://www.unither.com

1400

Name Title Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 1955
Mr. Michael I. Benkowitz Pres & COO 1972
Mr. James C. Edgemond CFO & Treasurer 1968
Mr. Paul A. Mahon J.D. Exec. VP, Gen. Counsel & Corp. Sec. 1964
Mr. Dewey Steadman C.F.A. Head of Investor Relations NA
Ms. Holly Hobson Associate VP of HR NA
Kevin T. Gray Sr. VP of Strategic Operations & Logistics NA
Mr. Patrick Poisson Exec. VP of Technical Operations 1968
Mr. Gil Golden Sr. VP & Chief Medical Officer NA
Dr. Leigh Peterson VP of Product Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…